For: | Fletcher J, Cooper SC, Swift A. Patient-Reported Outcomes in Inflammatory Bowel Disease: A Measurement of Effect in Research and Clinical Care. Gastroenterology Insights 2021;12:225-37. [DOI: 10.3390/gastroent12020020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis] |
---|
Number | Citing Articles |
1 | Peyrin-Biroulet L, Ghosh S, Lee SD, Lee WJ, Griffith J, Wallace K, Berg S, Liao X, Panes J, Loftus EV Jr, Louis E. Effect of risankizumab on health-related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials. Aliment Pharmacol Ther 2022. [PMID: 36266762 DOI: 10.1111/apt.17242] [Reference Citation Analysis] |
2 | Matini L, Ogden J. Early development of a novel scale to measure adaptation in people diagnosed with inflammatory bowel disease - the A-inflammatory bowel disease. Health Psychology Open 2022;9:205510292210985. [DOI: 10.1177/20551029221098550] [Reference Citation Analysis] |